全文获取类型
收费全文 | 18479篇 |
免费 | 912篇 |
国内免费 | 97篇 |
专业分类
耳鼻咽喉 | 317篇 |
儿科学 | 540篇 |
妇产科学 | 282篇 |
基础医学 | 2628篇 |
口腔科学 | 528篇 |
临床医学 | 1114篇 |
内科学 | 4371篇 |
皮肤病学 | 366篇 |
神经病学 | 1314篇 |
特种医学 | 713篇 |
外科学 | 3200篇 |
综合类 | 75篇 |
一般理论 | 1篇 |
预防医学 | 372篇 |
眼科学 | 243篇 |
药学 | 1202篇 |
中国医学 | 65篇 |
肿瘤学 | 2157篇 |
出版年
2023年 | 81篇 |
2022年 | 207篇 |
2021年 | 397篇 |
2020年 | 201篇 |
2019年 | 273篇 |
2018年 | 364篇 |
2017年 | 298篇 |
2016年 | 372篇 |
2015年 | 372篇 |
2014年 | 492篇 |
2013年 | 577篇 |
2012年 | 891篇 |
2011年 | 1022篇 |
2010年 | 578篇 |
2009年 | 473篇 |
2008年 | 805篇 |
2007年 | 925篇 |
2006年 | 931篇 |
2005年 | 981篇 |
2004年 | 1000篇 |
2003年 | 948篇 |
2002年 | 1062篇 |
2001年 | 533篇 |
2000年 | 499篇 |
1999年 | 453篇 |
1998年 | 272篇 |
1997年 | 232篇 |
1996年 | 211篇 |
1995年 | 174篇 |
1994年 | 178篇 |
1993年 | 166篇 |
1992年 | 397篇 |
1991年 | 344篇 |
1990年 | 299篇 |
1989年 | 316篇 |
1988年 | 266篇 |
1987年 | 230篇 |
1986年 | 212篇 |
1985年 | 230篇 |
1984年 | 188篇 |
1983年 | 116篇 |
1982年 | 63篇 |
1981年 | 53篇 |
1980年 | 53篇 |
1979年 | 79篇 |
1978年 | 59篇 |
1977年 | 59篇 |
1974年 | 57篇 |
1973年 | 60篇 |
1969年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
6.
Shiro Akinaga Tadashi Ashizawa Katsushige Gomi Hiroe Ohno Makoto Morimoto Chikara Murakata Masami Okabe 《Cancer chemotherapy and pharmacology》1992,29(4):266-272
Summary Novel derivatives of K-252a, (8R*,9S*,11S*)-(–)-9-hydroxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8, 11-epoxy-1H,8H,11H-2,7b,11a-triazadibenzo [a,g]-cycloocta[cde]trinden-1-one, an inhibitor of protein kinases and calmodulin-dependent phosphodiesterase, were synthesized and evaluated for their antitumor activity in vitro and in vivo. Of ten derivatives tested, four were active against the P388 murine leukemia i. p.-i. p. system, although K-252a was inactive. Among these derivatives, KT6124 was selected for further biological evaluation studies because its efficacy was the highest. KT6124 was also active against sarcoma 180 and B16 melanoma. It exerted a relatively broad spectrum of antiproliferative activity against 20 human tumor cell lines in vitro. To determine the mechanism(s) of action underlying the antitumor activity of KT6124, we tested the drug for inhibition of protein kinases, including Ca2+-and phospholipid-dependent protein kinase (PKC), in intact A431 human epidermoid carcinoma cells in comparison with the PKC-inhibitory activity of K-252a. KT6124 did not antagonize the action of phorbol 12-myristate 13-acetate (PMA) in A431 cells, whereas K-252a did, suggesting that KT6124 may not act on protein kinases in the cells. The interaction of KT6124 with DNA in living cells was examined by the alkaline elution method. KT6124 apparantly exhibited DNA scission both dose-and time-dependently in the target cells. The DNA breakage was dependent on proteinase K treatment, suggesting its possible interaction with DNA-related enzyme(s). These results indicate that KT6124 exerts antitumor activity by acting on DNA or on DNA-related enzyme(s) in tumor cells rather than via the inhibition of protein kinases. 相似文献
7.
8.
Tadashi Teshirogi M.D. Hiroeki Hosoi M.D. Yukashi Ohki M.D. Toshio Kagoshima M.D. 《Pediatrics international》1987,29(3):335-339
Residual pancreatic B-cell function was investigated in children with diabetes mellitus in whom classification of the type of disease was difficult at the first visit. Intravenous glucagon tests were performed at the first visit and subsequently, the C-peptide responses compared. Based on our data on a limited number of patients, we propose C-peptide concentrations of 3.0 to 3.5 ng/ml at the peak or at 6 min after injection of glucagon, as the critical level which distinguishes non-insulin dependent from insulin-dependent diabetes mellitus. However, the degree of obesity, clinical stage and other factors also need to be considered in the classification of diabetes mellitus. 相似文献
9.
Tadashi Kato 《Seishin shinkeigaku zasshi》2002,104(6):509-512
10.
Toru Takahashi Yutaka Hasegawa Kiyohiro Ohshima Taro Nameki Yasuo Morishita 《Annals of thoracic and cardiovascular surgery》2005,11(4):245-248
Although aortic valve replacement (AVR) is an effective treatment for patients with aortic valvular disease, the implantation of a small aortic prosthesis may result in residual left ventricular outflow stenosis and transvalvular gradient. In this study, the outcome in the long-term period of patients treated with a small aortic prosthesis was analyzed retrospectively. Twenty-four patients with AVR were divided into two groups, group A and group B. Group A consisted of 16 patients with 21 mm-sized prosthetic valves, and group B consisted of 8 patients with 19 or 16 mm-sized prosthetic valves. There were no significant differences in preoperative cardiac function or operative procedure in the two groups. The mean follow-up period (months) was 55.0 in group A and 51.3 in group B. RESULTS: One patient died of cerebral infarction in group A. There were no significant differences in cardiothoracic ratio (CTR), left ventricular ejection fraction (LVEF), and left ventricular mass index (LVMI) between the two groups. Postoperative physical activity according to the New York Heart Association (NYHA) classification showed no significant differences in the two groups. Despite using a small prostheses for AVR, the postoperative course was good in the long-term period, although careful follow-up is necessary. 相似文献